Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BackgroundAcute febrile illnesses (AFIs) represent a major disease burden globally; however, the paucity of reliable, rapid point-of-care testing makes their diagnosis difficult. A simple tool for distinguishing bacterial versus non-bacterial infections would radically improve patient management and reduce indiscriminate antibiotic use. Diagnostic tests based on host biomarkers can play an important role here, and a target product profile (TPP) was developed to guide development.ObjectivesTo qualitatively evaluate host biomarkers that can distinguish bacterial from non-bacterial causes of AFI.Data sourcesThe PubMed database was systematically searched for relevant studies published between 2015 and 2019.Study eligibility criteriaStudies comparing diagnostic performances of host biomarkers in patients with bacterial versus non-bacterial infections were included.ParticipantsStudies involving human participants and/or human samples were included.MethodsWe collected information following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. A risk of bias assessment was performed, based on a modified QUADAS-2 (Quality Assessment of Diagnostic Accuracy Score 2).ResultsWe identified 1107 publications. Following screening, 55 publications were included, with 265 biomarker entries. Entries mostly comprised protein biomarkers (58.9%), followed by haematological, RNA, and metabolite biomarkers (15.5%, 8.7%, 12.5%). Sensitivity/specificity was reported for 45.7% of biomarker entries. We assessed a high overall risk of bias for most entries (75.8%). In studies with low/medium risk of bias, four biomarker entries tested in blood samples had sensitivity/specificity of more than 0.90/0.80. Only 12 additional biomarker entries were identified with sensitivity/specificity of more than 0.65/0.65.ConclusionsMost recently assessed biomarkers represent well-known biomarkers, e.g. C-reactive protein and procalcitonin. Some protein biomarkers with the highest reported performances include a combined biomarker signature (CRP, IP-10, and TRAIL) and human neutrophil lipocalin (HNL). Few new biomarkers are in the pipeline; however, some RNA signatures show promise. Further high-quality studies are needed to confirm these findings.

Original publication

DOI

10.1016/j.jinf.2021.01.028

Type

Journal

The Journal of infection

Publication Date

04/2021

Volume

82

Pages

1 - 10

Addresses

Foundation for Innovative New Diagnostics (FIND), Chemin des Mines 9, Geneva, Switzerland. Electronic address: Leticia.fernandez@finddx.org.

Keywords

Humans, Fever, C-Reactive Protein, Sensitivity and Specificity, Lipocalins, Biomarkers, Procalcitonin